"SURUNKALI BUYRAK KASALLIGIDA OSTEOPOROZ RIVOJLANISHINING KLINIK-DIAGNOSTIK JIHATLARI"
Abstract
Kirish (Muammoning dolzarbligi)
Surunkali buyrak kasalligi (SBK) nafaqat nefronlarning yo‘qolishi, balki
mineral va suyak metabolizmining jiddiy buzilishi (CKD-MBD) bilan ham
xarakterlanadi. Qonda kreatinin darajasining oshishi buyrak funksiyasining
pasayishining klassik belgisi bo‘lsa, kaltsiy homeostazining buzilishi sekonder
giperparatiroidizm, osteoporoz va kardiovaskular asoratlar xavfini oshiradi. Bu ikki
ko‘rsatkich o‘rtasidagi bog‘liqlikni aniqlash va o‘rganish SBK ni kompleks baholash,
asoratlarni prognozlash va samarali terapiya yo‘lini belgilash uchun muhim
ahamiyatga ega.
References
Foydalanilgan Adabiyotlar:
1. Malluche HH, Mawad HW, Monier-Faugere MC. Renal osteodystrophy in the first
decade of the new millennium: analysis of 630 bone biopsies in black and white
patients. J Bone Miner Res. 2011;26(6):1368376.
2. Moe SM, Chertow GM, Parfrey PS, et al. Cinacalcet, fibroblast growth factor-23,
and cardiovascular disease in hemodialysis: the EVOLVE trial. Circulation.
2015;132(1):27-39.
3. Tentori F, Wang M, Bieber BA, et al. Recent changes in therapeutic approaches and
association with outcomes among patients with secondary hyperparathyroidism on
chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol. 2015;10(1):98-
109.
4. Block GA, Bushinsky DA, Cheng S, et al. Effect of etelcalcetide vs cinacalcet on
serum parathyroid hormone in patients receiving hemodialysis with secondary
hyperparathyroidism: a randomized clinical trial. JAMA. 2017;317(2):156-164.
5. Asaba K, Satoh M, Kadoya H, et al. The oral adsorbent AST-120 ameliorates bone
lesions in a rodent model of chronic kidney disease-mineral and bone disorder
(CKD-MBD). Bone. 2015;77:26-31.
6. Khairallah P, Nickolas TL. Management of osteoporosis in CKD. Clin J Am Soc
Nephrol. 2018;13(6):962-969.
